Production of a novel humanised anti Dendritic Cell Therapeutic Antibody for Graft Versus Host Disease [ 2007 - 2007 ]

Research Grant

Researchers: Dr David Munster (Principal investigator) ,  Prof Ross Barnard

Brief description A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.

Funding Amount $AUD 202,500.00

Funding Scheme NHMRC Development Grants

Notes Development Grant